Literature DB >> 12485897

Regulation of p53: intricate loops and delicate balances.

Moshe Oren1, Alexander Damalas, Tanya Gottlieb, Dan Michael, Jan Taplick, Juan Fernando Martinez Leal, Ruth Maya, Miri Moas, Rony Seger, Yoichi Taya, Avri Ben-Ze'Ev.   

Abstract

The p53 tumor suppressor protein provides a major anti-cancer defense mechanism, as underscored by the fact that the p53 gene is the most frequent target for genetic alterations in human cancer. Recent work has led to the realization that p53 lies at the hub of a very complex network of signaling pathways that integrate a variety of intracellular and extracellular inputs. Part of this network consists of an array of autoregulatory feedback loops, where p53 exhibits very intricate interactions with other proteins known to play important roles in the determination of cell fate. We discuss two such loops, one involving the beta-catenin protein and the other centering on the Akt/PKB protein kinase. In both cases, the central module is the interplay between p53 and the Mdm2 protein, which inactivates p53 and targets it for rapid proteolysis. Whereas deregulated beta-catenin can lead to Mdm2 inactivation and p53 accumulation, active p53 can promote the degradation and down-regulation of beta-catenin. Similarly, Akt can block p53 activation by potentiating Mdm2, whereas activated p53 can tune down Akt in several different ways. In each case, the actual output of the loop is determined by the delicate balance between the opposing effects of its different components. Often, this balance is dictated by additional signaling processes that occur simultaneously within the same cell. Genetic alterations characteristic of cancer are capable of severely distorting this balance, thereby overriding the tumor suppressor effects of p53 in a manner that facilitates neoplastic conversion.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12485897     DOI: 10.1111/j.1749-6632.2002.tb04669.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  19 in total

Review 1.  Role of E3 ubiquitin ligases in gastric cancer.

Authors:  Ya-Chao Hou; Jing-Yu Deng
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

2.  SnoN activates p53 directly to regulate aging and tumorigenesis.

Authors:  Deng Pan; Qingwei Zhu; Michael J Conboy; Irina M Conboy; Kunxin Luo
Journal:  Aging Cell       Date:  2012-08-27       Impact factor: 9.304

3.  MDM2 is required for suppression of apoptosis by activated Akt1 in salivary acinar cells.

Authors:  Kirsten H Limesand; Kathryn L Schwertfeger; Steven M Anderson
Journal:  Mol Cell Biol       Date:  2006-09-18       Impact factor: 4.272

Review 4.  Clinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancer.

Authors:  Aravind Suppiah; John Greenman
Journal:  World J Gastroenterol       Date:  2013-08-07       Impact factor: 5.742

5.  Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition.

Authors:  Mu-Shui Dai; Shelya X Zeng; Yetao Jin; Xiao-Xin Sun; Larry David; Hua Lu
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

6.  Identification of Akt interaction protein PHF20/TZP that transcriptionally regulates p53.

Authors:  Sungman Park; Donghwa Kim; Han C Dan; Huihua Chen; Joseph R Testa; Jin Q Cheng
Journal:  J Biol Chem       Date:  2012-02-14       Impact factor: 5.157

7.  SIRT3 deacetylates and promotes degradation of P53 in PTEN-defective non-small cell lung cancer.

Authors:  Yanlu Xiong; Lei Wang; Shan Wang; Mingxing Wang; Jinbo Zhao; Zhipei Zhang; Xiaofei Li; Lintao Jia; Yong Han
Journal:  J Cancer Res Clin Oncol       Date:  2017-11-04       Impact factor: 4.553

8.  CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53.

Authors:  Dingding Shi; Marius S Pop; Roman Kulikov; Ian M Love; Andrew L Kung; Andrew Kung; Steven R Grossman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-04       Impact factor: 11.205

9.  The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2.

Authors:  Lauren F Stevenson; Alison Sparks; Nerea Allende-Vega; Dimitris P Xirodimas; David P Lane; Mark K Saville
Journal:  EMBO J       Date:  2007-02-08       Impact factor: 11.598

10.  Topical delivery of DNA oligonucleotide to induce p53 generation in the skin via thymidine dinucleotide (pTT)-encapsulated liposomal carrier.

Authors:  Yi-Ping Fang
Journal:  Int J Nanomedicine       Date:  2011-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.